Precision Biosciences (DTIL) Total Non-Current Liabilities (2020 - 2026)

Precision Biosciences (DTIL) has reported Total Non-Current Liabilities for 7 consecutive years, with $45.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 30.87% year-over-year to $45.0 million; the TTM figure through Mar 2026 stood at $45.0 million (down 30.87% YoY), while the FY2025 annual figure was $46.5 million, down 33.61% from the prior year.
• Total Non-Current Liabilities retreated to $45.0 million in Q1 2026 per DTIL's latest filing, from $46.5 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $187.1 million in Q3 2022 and bottomed at $45.0 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $110.4 million across 5 years, with a median of $111.7 million in 2022.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 61.66% — and 2024, when it slumped 50.28%.
• Precision Biosciences' Total Non-Current Liabilities stood at $177.5 million in 2022, then declined by 20.7% to $140.8 million in 2023, then plunged by 50.28% to $70.0 million in 2024, then tumbled by 33.61% to $46.5 million in 2025, then slipped by 3.2% to $45.0 million in 2026.
• Business Quant data shows DTIL's Total Non-Current Liabilities at $45.0 million in Q1 2026, $46.5 million in Q4 2025, and $76.6 million in Q3 2025.